The term complement was introduced more than 100 years ago to refer to a group of plasma factors important in host defense and in the destruction of microorganisms. We now know that there are 3 separate activation pathways that appeared at different times in evolution: the classical, alternative, and lectin pathways. Two of these appear before the evolution of the adaptive immune system and do not require antibody for initiation. All pathways come together to activate C3, the principle opsonic protein of the complement cascade, and all continue together to the generation of biologically active factors, such as C5a, and to lysis of cells and microbes. In general, complete deficiencies of complement proteins are rare, although partial or complete deficiencies of one of the proteins that initiates the lectin pathway, mannose-binding lectin, are far more common. Although genetically controlled complement defects are rare, defects in the proteins in the circulation and on cell membranes that downregulate complement so as to limit uncontrolled inflammation are more common. A number of these are discussed, and because new methods of treatment are currently being introduced, one of these defects, CI inhibitor deficiency associated with hereditary angioedema, is discussed in some detail.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaci.2009.10.063 | DOI Listing |
JAAD Case Rep
February 2025
Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
J Comp Eff Res
January 2025
ICON plc, Insights, Evidence & Value - Health Economics & Epidemiology, Langen, Germany.
To compare the efficacy and safety of lanadelumab versus other approved long-term prophylaxis (LTP) treatments in patients with pediatric hereditary angioedema (HAE) aged <12 years. A systematic literature review was conducted to identify studies of LTP in patients with HAE aged <12 years. Two studies met the inclusion criteria in an indirect treatment comparison of efficacy and safety data in pediatric HAE patients.
View Article and Find Full Text PDFInt Arch Allergy Immunol
January 2025
Introduction: Hereditary angioedema (HAE) is a rare disease caused by dysfunction or lack of the C1 esterase inhibitor (C1-INH) protein. The true prevalence of HAE, and whether this prevalence differs across regions, is uncertain.
Methods: To estimate the prevalence of HAE worldwide, a systematic review and meta-analysis was performed.
JCI Insight
January 2025
Medicine, Washington University School of Medicine, St. Louis, United States of America.
Hereditary angioedema is an autosomal dominant disorder caused by defects in C1-esterase inhibitor (C1-INH), resulting in poorly controlled activation of the kallikrein-kinin system and bradykinin overproduction. C1-INH is a heavily glycosylated protein in the serine protease inhibitor (SERPIN) family, yet the role of these glycosylation sites remains unclear. To elucidate the functional impact of N-glycosylation in the SERPIN domain of C1-INH, we engineered four sets consisting of 26 variants at or near the N-linked sequon (NXS/T).
View Article and Find Full Text PDFJ Allergy Clin Immunol Glob
February 2025
Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong.
Background: Hereditary angioedema (HAE) is a rare genetic disorder with potentially life-threatening consequences, traditionally diagnosed by conventional laboratory methods that can be resource intensive and inconvenient. Incorporating dried blood spot (DBS) tests may be a promising alternative for diagnosing HAE and family screening.
Objective: This study aimed to validate DBS with conventional laboratory assays among confirmed C1 esterase inhibitor (C1-INH) HAE patients and assess the utility of DBS in a Screening Programme Providing Outreach for Testing Hereditary Angioedema (SPPOT-HAE).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!